

To the FDA:

RE: DOCKET NO. 98N-1265

I send this letter as a consumer of healthcare services to register my concern and disapproval of the Memorandum of Understanding as published by the FDA on January 21, 1999.

In its present form, the MOU, as well as the Compounding Section 503A of the Modernization Act, severely restricts the rights of the physicians and patients to obtain healthcare products from the provider of their choice. It also infringes on the rights of compounding pharmacists to serve the public's medical needs. As a healthcare consumer, there should be no restrictions to the delivery of a compounded medication prescribed for me, regardless of where I may live or may travel. The MOU must be amended!

Signed:

Marilyn R. Schwartz

State of Residence:


Louisiana

Comments:

The loss of individual compounding drugs will mean that I will not have an oral estrogen available as the FDA allows lactase in all prescription estrogens. And I am allergic to the patches

98N-1265

C 4139



DOCKETS MANAGEMENT BRANCH (HFA-305)
FOOD AND DRUG ADMINISTRATION
5630 FISHERS LN RM 1061
ROCKVILLE MD 20857-0003

